Want to see HK:2616 full AI Analyst Report?
2616 Stock Chart & Stats
HK$5.34
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.34
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.01 - HK$13.15
Previous CloseN/A
Volume1.16M
Average Volume (3M)19.75M
Market Cap
HK$6.82B
Enterprise ValueHK$7.15K
Total Cash (Recent Filing)HK$919.09M
Total Debt (Recent Filing)HK$348.67M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 20, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding1,600,749,100
10 Day Avg. Volume13,736,900
30 Day Avg. Volume19,747,038
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)10.65
Price to Sales (P/S)24.38
P/FCF Ratio-20.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)HK$412.50M
Bulls Say, Bears Say
Bulls Say
2025 Revenue ReboundA large 2025 revenue rebound (+47.7% YoY) indicates recovering demand and commercial traction for products or markets served. Sustained top-line growth can enable better operating leverage, support continued R&D and commercialization investment, and reduce reliance on external financing if maintained.
Improved LeverageMaterial reduction in debt-to-equity to ~0.57 from ~0.98 reflects an improved capital structure and lower leverage. Moderate leverage reduces near-term refinancing risk, gives more flexibility to fund clinical programs, and improves resilience versus a highly leveraged peer during funding stress.
Oncology-focused PipelineA strategic focus on targeted therapies and immuno-oncology aligns with durable structural demand in cancer treatment and strong partner/acquisition interest. A specialized oncology pipeline supports differentiated positioning, potential high-margin products, and long-term commercial opportunities if clinical success continues.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow (-328M in 2025) signals ongoing reliance on external financing to fund operations and trials. Persistent cash burn increases dilution and refinancing risk, constrains strategic optionality, and can impair long-term program execution if capital markets tighten.
Sharp Margin DeteriorationA collapse in gross margin and a swing to deeply negative net margins indicate worsening profitability dynamics and margin volatility. Such structural margin pressure undermines scalability, delays attainment of sustainable profitability, and forces greater dependence on revenue growth or cost restructuring to restore economics.
Negative Returns Eroding EquityA ~-69% ROE shows the company is destroying shareholder capital rather than generating returns. Persistent negative ROE diminishes the equity base, increases the likelihood of dilution or restructuring, and signals that current business economics are insufficient to reward long-term investors without material operational improvement.
CStone Pharmaceuticals News
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$4.01 and its highest was HK$13.15 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
CStone Pharmaceuticals’s market cap is HK$6.82B.
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Aug 20, 2026 which is in 12 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -HK$0.139 earnings per share for the quarter, missing the consensus estimate of -HK$0.058 by -HK$0.081.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Overvalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,600,749,100 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of -HK$0.139 in its last earnings report, missing expectations of -HK$0.058. Following the earnings report the stock price went up 0.145%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CStone Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
290.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.02%
Trailing 12-Months
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―